Circadian Genes and Risk for Prostate Cancer
Abstract
We propose that genetic susceptibility to prostate cancer may be in part due to variations in the core circadian genes that regulate circadian rhythms and that serum sex steroid hormone levels modify the effect of circadian gene polymorphisms on prostate cancer risk. Our study is nested within the Prostate Cancer Prevention Trial (PCPT), a randomized placebo-controlled clinical trial to determine if finasteride (an inhibitor of androgen bioactivation) could prevent prostate cancer. In Year 1 of the award, we have maintained communications with the PCPT Statistical Center, been involved in subject selection for the study, and have been involved in analyzing serum androgen data that will be used for Aim 2 of our study. In addition, we have been working with the Roswell Park Cancer Institute Microarray and Genotyping Facility to develop and quality check the genotyping assays for our study. We have determined that our SNP set will include 311 SNPs and that at least two different platforms are necessary to genotype the entire SNP set. These tasks have been accomplished in line with the approved statement of work and ensure that we are within our timeframe of completing the study.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2009
- Accession Number
- ADA524488
Entities
People
- Ann W Hsing